Department of Clinical and Biological Science, University of Turin, Corso Raffaello 30, 10125, Torino, Italy.
Department of Scienza e Tecnologia del Farmaco, University of Turin, Via Pietro Giuria 9, 10125, Turin, Italy.
Free Radic Biol Med. 2021 Oct;174:202-210. doi: 10.1016/j.freeradbiomed.2021.08.006. Epub 2021 Aug 5.
The intrinsic chemoresistance of pancreatic ductal adenocarcinoma (PDAC) represents the main obstacle in treating this aggressive malignancy. It has been observed that high antioxidant levels and upregulated Nrf2 and the YAP protein expression can be involved in PDAC chemoresistance. The mechanisms of Nrf2 and YAP increase need to be clarified. We chose a panel of PDAC cell lines with diverse sensitivity to cisplatin and gemcitabine. In PANC-1 chemoresistant cells, we found a low level of oxidative stress and high levels of Nrf2 and YAP protein expressions and their respective targets. On the contrary, in CFPAC-1 chemosensitive cells, we found high levels of oxidative stress and low level of these two proteins, as well as their respective targets. In MiaPaCa-2 cells with a middle chemoresistance, we observed intermediate features. When Nrf2 and YAP were inhibited in PANC-1 cells by Ailanthone, a plant extract, we observed a reduction of viability, thus sustaining the role of these two proteins in maintaining the PDAC chemoresistance. We then delved into the mechanisms of the Nrf2 and YAP protein upregulation in chemoresistance, discovering that it was at a post-translational level since the mRNA expressions did not match the protein levels. Treatments of PANC-1 cells with the proteasome inhibitor MG-132 and the protein synthesis inhibitor cycloheximide further confirmed this observation. The expression of DUB3 and OTUD1 deubiquitinases, involved in the control of Nrf2 and YAP protein level, respectively, was also investigated. Both protein expressions were higher in PANC-1 cells, intermediate in MiaPaCa-2 cells, and lower in CFPAC-1 cells. When DUB3 or OTUD1 were silenced, both Nrf2 and YAP expressions were downregulated. Importantly, in deubiquitinase-silenced cells, we observed a great reduction of proliferation and a higher sensitivity to gemcitabine treatment, suggesting that DUB3 and OTUD1 can represent a suitable target to overcome chemoresistance in PDAC cells.
胰腺导管腺癌 (PDAC) 的内在化疗耐药性是治疗这种侵袭性恶性肿瘤的主要障碍。已经观察到高水平的抗氧化剂和上调的 Nrf2 和 YAP 蛋白表达可能参与 PDAC 化疗耐药性。需要阐明 Nrf2 和 YAP 增加的机制。我们选择了一组对顺铂和吉西他滨敏感性不同的 PDAC 细胞系。在 PANC-1 耐药细胞中,我们发现氧化应激水平低,Nrf2 和 YAP 蛋白表达及其各自的靶标水平高。相反,在 CFPAC-1 化疗敏感细胞中,我们发现氧化应激水平高,这两种蛋白及其各自的靶标水平低。在中等化疗耐药的 MiaPaCa-2 细胞中,我们观察到了中间特征。当用植物提取物 Ailanthone 抑制 PANC-1 细胞中的 Nrf2 和 YAP 时,我们观察到细胞活力降低,从而维持了这两种蛋白在维持 PDAC 化疗耐药性中的作用。然后,我们深入研究了 Nrf2 和 YAP 蛋白在化疗耐药性中上调的机制,发现这是在翻译后水平上的,因为 mRNA 表达与蛋白水平不匹配。用蛋白酶体抑制剂 MG-132 和蛋白质合成抑制剂环己酰亚胺处理 PANC-1 细胞进一步证实了这一观察结果。还研究了参与控制 Nrf2 和 YAP 蛋白水平的 DUB3 和 OTUD1 去泛素酶的表达。两种蛋白表达在 PANC-1 细胞中较高,在 MiaPaCa-2 细胞中居中,在 CFPAC-1 细胞中较低。沉默 DUB3 或 OTUD1 后,Nrf2 和 YAP 的表达均下调。重要的是,在去泛素酶沉默的细胞中,我们观察到增殖大大减少,对吉西他滨治疗的敏感性更高,这表明 DUB3 和 OTUD1 可以成为克服 PDAC 细胞化疗耐药性的合适靶点。